

**Remarks**

Applicants have amended the claims to reduce the number of claims and to correct typographical errors. No new matter has been added.

Respectfully submitted,

By: John R. Van Amsterdam  
John R. Van Amsterdam, Reg No. 40,212  
Wolf, Greenfield & Sacks, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Telephone (617) 720-3500

Docket No. B0801/7170  
Dated: December 1, 2000  
**X12/02/00**

**Claims As Amended In Preliminary Amendment Of December 1, 2000**

6. (amended) The method of claim 1 [or 5], wherein the selectin polypeptide consists of a selectin selected from the group consisting of L-selectin, E-selectin and P-selectin.
7. (amended) The method of claim 1 [or 5], wherein the step of providing isolated dendritic cells comprises isolating dendritic cells from the subject and transfecting the isolated dendritic cells with a nucleic acid molecule which encodes the selectin polypeptide.
12. (amended) The method of claim 1 [or 5], wherein the step of providing isolated dendritic cells further comprises treating the isolated transfected dendritic cells with isolated activated platelets or membrane microparticles thereof which contain P selectin.
13. (amended) The method of claim 1 [or 5], wherein the isolated dendritic cells are administered intravenously.
19. (amended) The method of claim 14 [or 18], wherein the step of providing isolated dendritic cells further comprises culturing the isolated dendritic cells to expand the isolated dendritic cells.
20. (amended) The method of claim 14 [or 18], wherein the isolated platelet modified dendritic cells are administered intravenously.
30. (amended) The composition of claim 28, wherein the amount of the selectin polypeptide expressed on the cell surface is greater than the naturally occurring amount of the selectin [expressed on the cell surface *in vitro*] and is sufficient to target the genetically modified dendritic cells to peripheral lymph nodes.
37. (amended) A vaccine composition comprising the composition of [any of] claim[s] 28[-36] and an antigen.

48. (amended) A method for stimulating an immune response to an antigen in a subject comprising administering to the subject the vaccine composition of [any of] claim[s] 37[-46].